早期帕金森病中超阈值气味强度感知
Suprathreshold odor intensity perception in early-stage Parkinson's disease.
作者信息
Doty Richard L, Beals Evan, Osman Allen, Dubroff Jacob, Chung Inna, Leon-Sarmiento Fidias E, Hurtig Howard, Ying Gui-Shuang
机构信息
Smell and Taste Center, Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Mov Disord. 2014 Aug;29(9):1208-12. doi: 10.1002/mds.25946. Epub 2014 Jun 28.
BACKGROUND
Whether Parkinson's disease (PD) influences suprathreshold changes in perceived odor intensity is unknown. In patients with Alzheimer's disease, patients with schizophrenia, and the elderly, such perception is reportedly normal. If generally true, this could reflect a core element of the olfactory system insulated to some degree from age- and disease-related pathological conditions.
METHODS
Odor intensity ratings for pentyl acetate were obtained from 29 early-stage PD patients when on and off dopamine-related medications (DRMs) and from 29 matched controls.
RESULTS
The ratings were significantly attenuated at the higher odorant concentrations, with the degree of attenuation associated with overall olfactory dysfunction. Ratings were higher on the right than on the left side of the nose of both patients and controls. No associations with DRMs, Unified Parkinson's Disease Rating Scale (UPDRS) scores, or striatal dopamine transporter imaging were found.
CONCLUSIONS
Parkinson's disease (PD) influences suprathreshold estimates of perceived odor intensity, negating the notion that such perception might be spared in this disease. No association with dopaminergic processes was apparent.
背景
帕金森病（PD）是否会影响嗅觉强度超阈值变化尚不清楚。据报道，阿尔茨海默病患者、精神分裂症患者和老年人的这种嗅觉感知是正常的。如果普遍如此，这可能反映了嗅觉系统的一个核心要素在一定程度上不受年龄和疾病相关病理状况的影响。
方法
从29例早期帕金森病患者在服用和停用多巴胺相关药物（DRMs）时以及29例匹配的对照者那里获得了乙酸戊酯的气味强度评分。
结果
在较高气味浓度下，评分显著降低，降低程度与整体嗅觉功能障碍相关。患者和对照者鼻子右侧的评分均高于左侧。未发现与多巴胺相关药物、统一帕金森病评定量表（UPDRS）评分或纹状体多巴胺转运体成像有相关性。
结论
帕金森病（PD）会影响嗅觉强度超阈值估计，这否定了这种嗅觉感知在该疾病中可能不受影响的观点。未发现与多巴胺能过程有明显关联。
Zotero 插件